299 related articles for article (PubMed ID: 32571429)
1. Timing of antiretroviral therapy for HIV-infected patients with moderate to severe Pneumocystis pneumonia: study protocol for a multi-centre prospective randomised controlled trial.
Qin Y; Lu Y; Zhou Y; Harypursat V; Sun F; Yang S; Tang S; Li Y; He X; Zeng Y; Chen Y
Trials; 2020 Jun; 21(1):551. PubMed ID: 32571429
[TBL] [Abstract][Full Text] [Related]
2. Initiating antiretroviral therapy within 2 weeks of anti-Pneumocystis treatment does not increase mortality or AIDS-defining events in patients with HIV-associated moderate to severe Pneumocystis pneumonia: results of a prospective observational multicenter study.
Zeng YM; Li Y; Lu YQ; Liu M; Nie JM; Yuan J; Harypursat V; Zhou YH; Qin YY; Chen XH; Zhang YL; Zhang DF; Wang N; Chen H; Tian Q; Zhou Y; Qin YM; Yang XP; Chen YK
BMC Pulm Med; 2022 Aug; 22(1):323. PubMed ID: 36008855
[TBL] [Abstract][Full Text] [Related]
3. Timing of antiretroviral therapy for HIV-infected patients with cytomegalovirus retinitis: study protocol of a multi-center prospective randomized controlled trial.
He XQ; Huang YQ; Zeng YM; Qin YY; Tang SQ; Xu XL; Harypursat V; Lu YQ; Liu M; Yuan J; Chen YK
Trials; 2021 Mar; 22(1):218. PubMed ID: 33736696
[TBL] [Abstract][Full Text] [Related]
4. Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study).
Schäfer G; Hoffmann C; Arasteh K; Schürmann D; Stephan C; Jensen B; Stoll M; Bogner JR; Faetkenheuer G; Rockstroh J; Klinker H; Härter G; Stöhr A; Degen O; Freiwald E; Hüfner A; Jordan S; Schulze Zur Wiesch J; Addo M; Lohse AW; van Lunzen J; Schmiedel S;
AIDS Res Ther; 2019 Nov; 16(1):34. PubMed ID: 31729999
[TBL] [Abstract][Full Text] [Related]
5. A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections: Study protocol for antiretroviral therapy timing in AIDS patients with toxoplasma encephalitis.
Zeng YM; Li Y; He XQ; Huang YQ; Liu M; Yuan J; Bai Y; Lu YQ; Li H; Chen YK
Medicine (Baltimore); 2020 Jul; 99(29):e21141. PubMed ID: 32702867
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of the Efficacy of Early Antiretroviral Therapy in HIV-1-Infected Patients Coinfected with
Kasahara T; Imahashi M; Hashiba C; Mori M; Kogure A; Yokomaku Y; Hashimoto N; Iwatani Y; Hasegawa Y
AIDS Res Hum Retroviruses; 2021 Oct; 37(10):754-760. PubMed ID: 34235941
[TBL] [Abstract][Full Text] [Related]
7. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
[TBL] [Abstract][Full Text] [Related]
9. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
[TBL] [Abstract][Full Text] [Related]
10. Pneumocystis jirovecii pneumonia in Latin America. A public health problem?
Calderón EJ; de Armas Y; Panizo MM; Wissmann G
Expert Rev Anti Infect Ther; 2013 Jun; 11(6):565-70. PubMed ID: 23750728
[TBL] [Abstract][Full Text] [Related]
11. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
[TBL] [Abstract][Full Text] [Related]
12. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
[TBL] [Abstract][Full Text] [Related]
13. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database.
Lim PL; Zhou J; Ditangco RA; Law MG; Sirisanthana T; Kumarasamy N; Chen YM; Phanuphak P; Lee CK; Saphonn V; Oka S; Zhang F; Choi JY; Pujari S; Kamarulzaman A; Li PC; Merati TP; Yunihastuti E; Messerschmidt L; Sungkanuparph S;
J Int AIDS Soc; 2012 Jan; 15(1):1. PubMed ID: 22281054
[TBL] [Abstract][Full Text] [Related]
14. Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis.
Abgrall S; Matheron S; Le Moing V; Dupont C; Costagliola D;
J Acquir Immune Defic Syndr; 2001 Feb; 26(2):151-8. PubMed ID: 11242182
[TBL] [Abstract][Full Text] [Related]
15. Serum-based diagnosis of Pneumocystis pneumonia by detection of Pneumocystis jirovecii DNA and 1,3-β-D-glucan in HIV-infected patients: a retrospective case control study.
Hammarström H; Grankvist A; Broman I; Kondori N; Wennerås C; Gisslen M; Friman V
BMC Infect Dis; 2019 Jul; 19(1):658. PubMed ID: 31337356
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.
Huang YS; Yang JJ; Lee NY; Chen GJ; Ko WC; Sun HY; Hung CC
Expert Rev Anti Infect Ther; 2017 Sep; 15(9):873-892. PubMed ID: 28782390
[TBL] [Abstract][Full Text] [Related]
17. Dihydropteroate synthase (DHPS) gene mutation study in HIV-Infected Indian patients with Pneumocystis jirovecii pneumonia.
Tyagi AK; Mirdha BR; Luthra K; Guleria R; Mohan A; Singh UB; Samantaray JC; Dar L; Iyer VK; Chaudhry R
J Infect Dev Ctries; 2010 Nov; 4(11):761-6. PubMed ID: 21252456
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
[TBL] [Abstract][Full Text] [Related]
19. Prescription of Pneumocystis Jiroveci Pneumonia Prophylaxis in HIV-Infected Patients.
Lin X; Garg S; Mattson CL; Luo Q; Skarbinski J
J Int Assoc Provid AIDS Care; 2016 Nov; 15(6):455-458. PubMed ID: 27629868
[TBL] [Abstract][Full Text] [Related]
20. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.
Naidoo K; Yende-Zuma N; Padayatchi N; Naidoo K; Jithoo N; Nair G; Bamber S; Gengiah S; El-Sadr WM; Friedland G; Abdool Karim S
Ann Intern Med; 2012 Sep; 157(5):313-24. PubMed ID: 22944873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
